Finally, the upregulation of the PCSK9-repressor miR-224-5p appeared to be the mechanism by which the intraperitoneally administration of Diminazene, a modulator of the renin-angiotensin system, inhibited the expression of NLRP3 in astrocytes of AD mice, halting neuroinflammation, alleviating neuronal and synaptic damage, and ameliorating cognitive impairment [165]. The gene discussed is NLRP3; the disease is Alzheimer disease.